1. Home
  2. MNY vs IFRX Comparison

MNY vs IFRX Comparison

Compare MNY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

N/A

Current Price

$1.44

Market Cap

54.1M

Sector

N/A

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$0.93

Market Cap

60.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNY
IFRX
Founded
2014
2007
Country
Singapore
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.1M
60.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MNY
IFRX
Price
$1.44
$0.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$4.00
$8.50
AVG Volume (30 Days)
45.0K
188.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.58
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.71
52 Week High
$2.40
$1.94

Technical Indicators

Market Signals
Indicator
MNY
IFRX
Relative Strength Index (RSI) 56.87 52.09
Support Level $1.31 $0.81
Resistance Level $1.52 $1.16
Average True Range (ATR) 0.06 0.06
MACD 0.00 0.01
Stochastic Oscillator 50.00 64.20

Price Performance

Historical Comparison
MNY
IFRX

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: